SINGH BIOTECHNOLOGY, LLC
LUTZ, FLORIDA

Singh Biotechnology (SBT) is a privately held biotechnology company situated in Tampa Bay, Florida. Established on October 10, 2014, SBT specializes in the discovery and development of unique proprietary therapeutic agents aimed at treating various diseases, including cancers, autoimmune disorders, and ophthalmologic conditions. At the core of their operations is an innovative single domain antibody (sdAb) technology platform, which allows SBT to engineer miniature antibodies consisting solely of the variable region, eliminating light chains in the process. These sdAbs are specifically designed to be both specific and bi-specific, with capabilities that include crossing cellular and blood-brain barriers to target intracellular proteins critical in disease pathogenesis. Singh Biotechnology has achieved significant milestones such as obtaining orphan drug designation from the United States Food and Drug Administration (FDA) for its anti-STAT3 B VHH13 sdAb, branded SBT-100. As of its latest filings, SBT maintains a business presence at 1547 Fox Grape Loop, Lutz, FL, and can be contacted via phone numbers (727) 222-0806 or (727) 233-9737. Managed by Sunanda Singh as the Director and Manager, the company's operations are anchored in Hillsborough County with a registration status of FLAL. SBT is committed to continued innovation, aligning its strategic goals with regulatory approval processes and market development for pioneering treatments.